Literature DB >> 2800585

Pharmacoeconomic research and clinical trials: concepts and issues.

J L Bootman1, L N Larson, W F McGhan, R J Townsend.   

Abstract

The purpose of this article is to provide an overview of the emerging discipline of pharmacoeconomics. Specific methodologies and terms are defined. Pharmacoeconomic research is described, related to, and contrasted with clinical drug trials. Additionally, we present a brief overview of the general steps taken designing a pharmacoeconomic study. Finally, several issues centering around pharmacoeconomic analysis are presented for discussion and debate. The need for high-quality pharmacoeconomic research is stressed along with the need for appropriate education of individuals trained in the health sciences.

Mesh:

Year:  1989        PMID: 2800585     DOI: 10.1177/106002808902300913

Source DB:  PubMed          Journal:  DICP        ISSN: 1042-9611


  9 in total

1.  Waste gas monitor reduces wasted volatile anesthetic.

Authors:  T Y Euliano; J H van Oostrom; J van der Aa
Journal:  J Clin Monit Comput       Date:  1999-07       Impact factor: 2.502

2.  Pharmacoeconomic evaluation to assist prescription drug pricing: a US perspective on an international issue.

Authors:  R J Bonk; W F McGhan
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

Review 3.  Drug utilisation studies as tools in health economics.

Authors:  J A Sacristán; J Soto
Journal:  Pharmacoeconomics       Date:  1994-04       Impact factor: 4.981

4.  Strategic use of pharmacoeconomic research in early drug development and global pricing.

Authors:  K Clemens; L P Garrison; A Jones; F Macdonald
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

5.  Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America.

Authors:  K Clemens; R Townsend; F Luscombe; J Mauskopf; J Osterhaus; J Bobula
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

6.  The defined daily dose as a tool in pharmacoeconomics. Advantages and limitations.

Authors:  K W Clarke; D Gray
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

7.  Prednicarbate versus fluocortin for inflammatory dermatoses. A cost-effectiveness study.

Authors:  A de Tiedra; J Mercadal; R Lozano
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

8.  Anaesthesia pharmacoeconomics.

Authors:  D R Bevan
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

9.  Evaluation of cost minimization strategies of anaesthetic drugs in a tertiary care hospital.

Authors:  C Hawkes; D Miller; R Martineau; K Hull; H Hopkins; M Tierney
Journal:  Can J Anaesth       Date:  1994-10       Impact factor: 5.063

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.